Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease
05 juin 2018 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...